Skip to content

Viral Vectors for Vaccines and Gene Delivery

Viral vectors for vaccine, and cell and gene therapy products have shown unprecedented clinical promise; however the manufacturing platforms for their commercial production are in their infancy when compared to therapeutic proteins. When analysing current process performance, major challenges emerge in both upstream and downstream operations: in USP the low titre and presence of large proportions of product-related impurities, in DSP low yields / loss of infectivity and the separation of product-related impurities. Furthermore, there is a need for advances in analytical capabilities in order to better understand viral vector products and critical quality attributes and to enable a Quality by Design philosophy.

This symposium will look at USP and DSP and the common analytical challenges across the major viral vector products. We will also seek to learn from other virus manufacturing processes e.g. those for flu vaccine.

This one-day meeting is open to all and offers a programme of invited talks, a poster session and an interactive session. The event has been organised by the Future Vaccine Manufacturing Research Hub (Vax-Hub), the Future Targeted Healthcare Manufacturing Hub and the Knowledge Transfer Network (KTN).

Tony Hitchcock, Techical Director Cobra Biologics, is scheduled to present during Session 1 at 10:55. If you would like to pre-arrange an informal meeting with Tony, please complete the request form below.

Tony Hitchcock

Arrange your meeting

To arrange a meeting with us, please contact us.

We use cookies to give you the best experience of using this website. By continuing to use this site, you accept our use of cookies. Please read our Cookie Policy for more information.